Sun Pharma to acquire Organon in an all-cash deal
Revenue nearly doubles; expands into women’s health and biosimilars
Signals shift to innovation-led global growth
In a defining move for India’s pharmaceutical sector, Sun Pharmaceutical Industries announced on Monday, April 27, the acquisition of US-listed Organon & Co. in an all-cash deal valued at $11.75 billion. Priced at $14 per share, the transaction is the largest-ever overseas acquisition by an Indian drugmaker and signals Sun Pharma’s intent to evolve into a more diversified, innovation-driven global player.
The deal significantly expands Sun Pharma’s footprint across high-value segments, including women’s health, biosimilars, and established branded medicines. Organon operates in over 140 countries and brings a strong portfolio spanning contraceptives, fertility treatments, and more than 50 established brands—along with a fast-growing biosimilars pipeline.
4 July 2026
Get the latest issue of Outlook Business
Shares of Sun Pharma rallied 6.76% on Monday after the announcement of the acquisition.
What Comes Next After the Deal
Post-acquisition, the combined entity is expected to generate annual revenues of about $12.4 billion, nearly doubling Sun Pharma’s current scale. EBITDA is projected at $3.7 billion, reflecting improved profitability and a more balanced business mix.
Importantly, the merger reduces reliance on commoditised generics by increasing exposure to branded and innovative therapies.
Sun Pharma plans to fund the deal through a mix of internal cash and committed bank financing. Despite the large outlay, leverage is expected to remain under control, supported by Organon’s robust cash flows, which exceed $1 billion annually. These funds will also help accelerate debt reduction after the acquisition.
Advertisement
Why It Matters Now
The acquisition comes as global pharma companies increasingly pivot toward specialty and innovation-led segments. For Sun Pharma, this is a timely opportunity to add a new growth pillar—women’s health—while strengthening its presence in advanced markets.
Management expects synergies exceeding $350 million within four years, driven by cost efficiencies, supply chain optimisation, and cross-market product expansion. The company also sees potential in leveraging Organon’s commercial network to scale new therapies globally.
With closing expected in early 2027, the combined business will have a strong presence across major markets and a workforce of around 24,000. The deal positions Sun Pharma as a more formidable global competitor, capable of driving sustained growth beyond traditional generics.
